We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Unlocking Cures: How AI is Reshaping Cancer Research & Healthcare ETFs?
Read MoreHide Full Article
The integration of artificial intelligence (AI) in the U.S. healthcare industry, including cancer research, has witnessed a rapid acceleration in recent years, which has transformed clinical practice, diagnostics, and operational efficiency across hospitals and providers. While this rapid integration bears a few crucial challenges, like a lack of robust data governance and regulatory frameworks for patient safety and privacy, no one can deny the immense benefit AI has been providing across every area of health care, from personalized medicine to automated workflows.
In 2024, North America contributed approximately 44.7% of global market revenue for AI in oncology, per a report by the Morder Intelligence firm. This statistic reflects how deep-rooted a growth catalyst AI has become for the American cancer research market, and a positive outlook for the healthcare sector created by its widespread adoption, as is evident from the improved performance of several major healthcare ETFs this year compared to their 2024 performance. This trend is poised to continue with the latest federal action providing a targeted boost to a critical area of the oncology market.
A Presidential Push for Pediatric Cancer & ETF Landscape
On Sept. 30, 2025, President Donald Trump signed an executive order that doubled the U.S. National Institutes of Health’s investment in a childhood cancer data initiative, launched during Trump’s first term, with an additional $50 million. The order recognizes pediatric cancer as the leading cause of disease-related death for American children. It seeks to harness American AI innovation to reverse this trend by improving data infrastructure, enhancing the analysis of complex biological systems, and designing better clinical trials.
No doubt this executive order lays a crucial groundwork for further boosting healthcare ETF performance, especially for funds exposed to pediatric cancer innovation. Healthcare companies such as Johnson & Johnson, Merck, Eli Lily and Boston Scientific—which already play significant roles in pediatric cancer therapies and have adopted AI-driven diagnostics — should benefit. Consequently, healthcare ETFs, like Vanguard Health Care ETF ((VHT - Free Report) ) and iShares Global Healthcare ETF ((IXJ - Free Report) ), with heavy exposure to these companies, should witness improved performance in the coming days.
Healthcare ETFs in Focus
A confluence of factors, including strong M&A activity, a wave of high-impact pharmaceutical and medical device product launches, favorable demographic tailwinds from an aging U.S. population with elevated healthcare utilization, and increased use of AI in healthcare, are boosting healthcare ETFs in 2025 over their 2024 performance.
Given these factors, combined with the recent executive order on pediatric cancer and AI innovation, it makes sense to put the spotlight on healthcare ETFs that have significant exposure to U.S. companies advancing in these areas.
This fund provides exposure to U.S. companies that manufacture healthcare equipment and supplies or that provide healthcare-related services, and companies that are primarily involved in the research, development, production, and marketing of pharmaceuticals and biotechnology products. Its top three holdings are in U.S.-based pharmaceutical and biotechnology companies- Eli Lily (10.16%), AbbVie (5.38%) and Johnson & Johnson (5.07%), all of which are involved in pediatric cancer research.
VHT rose 1% in 2024 and are up 2.3% so far this year. The fund charges 9 basis points (bps) as fees.
This fund offers exposure to pharmaceutical, biotechnology and medical device companies. Its top three holdings are in Eli Lily (8.21%), Johnson & Johnson (6.21%) and AbbVie (5.60%).
IXJ lost 1.1% in 2024 but has soared 3.1% so far this year. The fund charges 40 bps as fees.
This fund provides exposure to a broad range of companies in the biotechnology sector. Its top three holdings constitute U.S.-based biotechnology companies Exelixis Inc. (1.97%) and United Therapeutics (1.96%) both of which are involved in pediatric cancer research and support.
XBI inched up 0.7% in 2024 but has surged 11.3% so far this year. The fund charges 35 bps as fees.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Unlocking Cures: How AI is Reshaping Cancer Research & Healthcare ETFs?
The integration of artificial intelligence (AI) in the U.S. healthcare industry, including cancer research, has witnessed a rapid acceleration in recent years, which has transformed clinical practice, diagnostics, and operational efficiency across hospitals and providers. While this rapid integration bears a few crucial challenges, like a lack of robust data governance and regulatory frameworks for patient safety and privacy, no one can deny the immense benefit AI has been providing across every area of health care, from personalized medicine to automated workflows.
In 2024, North America contributed approximately 44.7% of global market revenue for AI in oncology, per a report by the Morder Intelligence firm. This statistic reflects how deep-rooted a growth catalyst AI has become for the American cancer research market, and a positive outlook for the healthcare sector created by its widespread adoption, as is evident from the improved performance of several major healthcare ETFs this year compared to their 2024 performance. This trend is poised to continue with the latest federal action providing a targeted boost to a critical area of the oncology market.
A Presidential Push for Pediatric Cancer & ETF Landscape
On Sept. 30, 2025, President Donald Trump signed an executive order that doubled the U.S. National Institutes of Health’s investment in a childhood cancer data initiative, launched during Trump’s first term, with an additional $50 million. The order recognizes pediatric cancer as the leading cause of disease-related death for American children. It seeks to harness American AI innovation to reverse this trend by improving data infrastructure, enhancing the analysis of complex biological systems, and designing better clinical trials.
No doubt this executive order lays a crucial groundwork for further boosting healthcare ETF performance, especially for funds exposed to pediatric cancer innovation. Healthcare companies such as Johnson & Johnson, Merck, Eli Lily and Boston Scientific—which already play significant roles in pediatric cancer therapies and have adopted AI-driven diagnostics — should benefit. Consequently, healthcare ETFs, like Vanguard Health Care ETF ((VHT - Free Report) ) and iShares Global Healthcare ETF ((IXJ - Free Report) ), with heavy exposure to these companies, should witness improved performance in the coming days.
Healthcare ETFs in Focus
A confluence of factors, including strong M&A activity, a wave of high-impact pharmaceutical and medical device product launches, favorable demographic tailwinds from an aging U.S. population with elevated healthcare utilization, and increased use of AI in healthcare, are boosting healthcare ETFs in 2025 over their 2024 performance.
Given these factors, combined with the recent executive order on pediatric cancer and AI innovation, it makes sense to put the spotlight on healthcare ETFs that have significant exposure to U.S. companies advancing in these areas.
Vanguard Health Care ETF (VHT - Free Report)
This fund provides exposure to U.S. companies that manufacture healthcare equipment and supplies or that provide healthcare-related services, and companies that are primarily involved in the research, development, production, and marketing of pharmaceuticals and biotechnology products. Its top three holdings are in U.S.-based pharmaceutical and biotechnology companies- Eli Lily (10.16%), AbbVie (5.38%) and Johnson & Johnson (5.07%), all of which are involved in pediatric cancer research.
VHT rose 1% in 2024 and are up 2.3% so far this year. The fund charges 9 basis points (bps) as fees.
iShares Global Healthcare ETF (IXJ - Free Report)
This fund offers exposure to pharmaceutical, biotechnology and medical device companies. Its top three holdings are in Eli Lily (8.21%), Johnson & Johnson (6.21%) and AbbVie (5.60%).
IXJ lost 1.1% in 2024 but has soared 3.1% so far this year. The fund charges 40 bps as fees.
SPDR S&P Biotech ETF ((XBI - Free Report) )
This fund provides exposure to a broad range of companies in the biotechnology sector. Its top three holdings constitute U.S.-based biotechnology companies Exelixis Inc. (1.97%) and United Therapeutics (1.96%) both of which are involved in pediatric cancer research and support.
XBI inched up 0.7% in 2024 but has surged 11.3% so far this year. The fund charges 35 bps as fees.